Publication date: Available online 27 June 2019
Source: Critical Reviews in Oncology/Hematology
Author(s): Patrizia Mondello, Michael Mian, Francesco Bertoni
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of diffuse large B-cell lymphoma. The frontline treatment with high-dose methotrexate based immunochemotherapy is not curative for the majority of patients. Gene expression profiling and next-generation sequencing have recently provided plethora of data shedding light on pathogenic mechanisms sustain PCNSL and identifying potential vulnerable mechanisms to be explored therapeutically. Here, we review established molecular drivers of PCNSL and targeted drugs that may change the current therapeutic paradigm.
No comments:
Post a Comment